Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836849 | 1.00 | GUSB (0.51) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL9329946 | 0.83 | GUSB (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL9329953 | 0.83 | GUSB (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL12924107 | 0.82 | HCAR2 (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL1126746 | 0.82 | HCAR2 (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL1126747 | 0.82 | HCAR2 (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL9256644 | 0.80 | GLA (0.53) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL1384049 | 0.80 | ALOX5 (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL1478122 | 0.80 | ALOX5 (0.54) | GUSBTAS1R3TAS1R1ALOX5JAK2 | |
| SCHEMBL9256654 | 0.80 | GLA (0.53) | GUSBTAS1R3TAS1R1ALOX5JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415561-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023062110-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2023-04-20 | — | — | WO | disclosed |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6713482-B2 | SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS | PFIZER INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6323212-B1 | METHOD FOR REDUCING PAIN, WHICH COMPRISES ADMINISTERING AN EFFECTIVE ANALGESIC AMOUNT OF THE MORPHINAN DERIVATIVE | TORAY INDUSTRIES, INC. (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| US-6277859-B1 | HIGHLY SELECTIVE KAPPA-OPIOID AGONISTS USEFUL AS ANALGESICS AND DIURETICS WITH REDUCED PHYSIOLOGICAL SIDE EFFECTS | TORAY INDUSTRIES, INC. (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6177438-B1 | ANALGESICS, DIURETICS, ANTITUSSIVE AGENTS | TORAY INDUSTRIES, INC. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0661283-B1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES (JP) | 1998-10-21 | — | — | EP | disclosed |
| EP-0577847-B1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0846694-A1 | Morphinan derivative and its pharmaceutical applications | TORAY INDUSTRIES, INC. (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0541617-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 1997-06-04 | — | — | EP | disclosed |
| EP-0663401-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1995-07-19 | — | — | EP | disclosed |
| EP-0661283-A1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES, INC. (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0577847-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-5276035-A | Central nervous system disorders; Parkinson's disease; antidepressant and dopaminergic agent | NOVO NORDISK A/S (DK) | 1994-01-04 | — | — | US | disclosed |
| EP-0541617-A1 | 1,4-DISUBSTITUTED PIPERAZINES. | NOVO NORDISK AS (DK) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992001679-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | GUSB 4372/4885TAS1R3 1052/4885TAS1R1 635/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | GUSB 4461/4885TAS1R3 1076/4885TAS1R1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.